Revvity高层指出,生命科学部门的下滑背后,其实隐藏着一个关键推手——公司旗下的Signal软件业务因合同签订时点的影响,营收大幅萎缩了大约20%。这一披露引发了市场对其短期业绩波动的更多关注。
Revvity高层指出,生命科学部门的下滑背后,其实隐藏着一个关键推手——公司旗下的Signal软件业务因合同签订时点的影响,营收大幅萎缩了大约20%。这一披露引发了市场对其短期业绩波动的更多关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.